Header Logo

Connection

Parameswaran Venugopal to Treatment Outcome

This is a "connection" page, showing publications Parameswaran Venugopal has written about Treatment Outcome.
Connection Strength

0.147
  1. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431.
    View in: PubMed
    Score: 0.031
  2. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 01 21; 137(3):374-386.
    View in: PubMed
    Score: 0.030
  3. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 07; 186(1):45-53.
    View in: PubMed
    Score: 0.026
  4. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
    View in: PubMed
    Score: 0.016
  5. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.
    View in: PubMed
    Score: 0.013
  6. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
    View in: PubMed
    Score: 0.011
  7. Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation. Clin Adv Hematol Oncol. 2006 Aug; 4(8):600-4; discussion 604-6.
    View in: PubMed
    Score: 0.011
  8. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.